The knowledge that EGR1 expression is regulated by the MAPK signaling pathway [34] prompted us to employ Trametinib, the MEK1/2 inhibitor FDA-approved compound for melanoma, as a tool to reduce EGR1-TFEB expression in TFEB-driven cancers. This evidence concerns the gene MAP2K1 and cancer.